The p85a subunit of PI3-K and Btk are two crucial components of the B-cell receptor (BCR) signalling pathway. In the present study, we showed that primary splenic B cells from p85a null and xid (Btk-deficient) mice fail to induce cyclin D2 expression and enter early G1, but not S phase of the cell cycle in response to BCR engagement. Furthermore, these Btk or p85a null B cells displayed increased cell death compared with wild type following BCR engagement. These findings are further confirmed by studies showing that specific pharmacological inhibitors of Btk (LFM-A13), PI3-K (LY294002 and Wortmannin) and PLCc (U73122) also block cyclin D2 expression and S phase entry following BCR stimulation, as well as triggering apoptosis. Collectively, these data provide evidence for the concept that the B-cell signalosome (p85a, Btk, BLNK and PLCc) is involved in regulating cyclin D2 expression in response to BCR engagement. PKC and intracellular calcium are two major downstream effectors of the B-cell signalosome and can be activated by PMA and ionomycin, respectively. In small resting (G0) B cells, costimulation with PMA and ionomycin, but not PMA or ionomycin alone, induces cyclin D2 expression and cell-cycle progression. Consistent with this, we also showed that the BCR-mediated cyclin D2 induction could be abolished by pretreatment of resting B cells with specific inhibitors of capacitative Ca 2+ entry (SK&F 96365) or PKC (Go¨6850). Our present results lead us to propose a model in which the B-cell signalosome targets cyclin D2 via the Ca 2+ and PKCdependent signalling cascades to mediate cell-cycle progression in response to BCR engagement.
Introduction
Bruton's tyrosine kinase (Btk), a member of the Tec family of nonreceptor tyrosine kinases, is a central molecule of the B-cell signalosome and is essential for early B-cell development and mature B-cell activation and survival (Tsukada et al., 1994 Satterthwaite et al., 1998) . Mutations to the btk gene are responsible for the inherited severe immunodeficiency disease Xchromosome linked agammaglobulinaemia (XLA) in humans (Vihinen et al., 1997) and X-linked immunodeficiency (Xid) in mice (Vihinen et al., 1995) . The human XLA phenotype includes the lack of mature circulating B cells and immunoglobulins. In mice, Xid manifested itself in the CBA/N mice, a naturally occurring variant of CBA/J strain. The Xid-CBA/N mice display defects, including reduction of IgM and IgG 3 levels, depletion of the CD5-positive (B1) subset of B cells, lack of immunoresponse to T-independent antigens and attenuated B-cell proliferative response to anti-IgM and anti-CD38. p85a is the most prevalent PI3-K regulatory subunit expressed in mammalian cells. Phosphoinositide 3-kinases (PI3-Ks) are a family of lipid kinases that catalyse the specific phosphorylation of the inositol ring of phosphoinositides at position 3, and are involved in a variety of cellular responses, including cell growth, survival, metabolism, differentiation, cytoskeletal organization and membrane trafficking (Leevers et al., 1999) . The common Class 1A PI3-Ks are composed of a 110 kDa catalytic and a regulatory subunit encoded by either of three genes p85a, p85b, p55g. The p85a is the most prevalent PI3-K regulatory subunit in mammalian cells. When activated, the p85 subunit recruits and activates the p110 subunits at the plasma membrane. Besides p85a, the p85a locus also encodes for another two additional minor alternative splice peptide products, p55a and p50a. Gene targeted deletion of the p85a subunit results in severe impairment of B-cell function and development almost, though not exactly, identical to those observed in xid mice, indicating that p85a is functionally linked to Btk in B-cell receptor (BCR) signalling. Indeed, one of the products of the PI3-K, PIP 3 (phosphatidylinositol-3,4,5-trisphosphate) is responsible for recruiting Btk to the cellular membrane.
Signals emanating from the BCR following engagement play an important role in B-lymphocyte proliferation and development (Kurosaki, 1999 (Kurosaki, , 2000 . Engagement of the BCR results in the activation of nonreceptor protein tyrosine kinases (PTKs), including Syk and the Src family of kinases Lyn, Fyn and Blk (Rawlings et al., 1996; Kurosaki, 1999) . It is proposed that activation of these PTKs leads to the assembly and activation of a molecular scaffold called 'the B cell signalosome', consisting of the adapter protein BLNK (B-cell linker protein, also called SLP-65 and BASH), the tyrosine kinase Btk, the lipid kinase p85/p110 phosphatidylinositol 3-kinase (PI3-K) and phospholipase Cg2 (PLCg2) (Fruman et al., 2000; DeFranco, 2001) . Upon BCR stimulation, the adapter molecule BLNK, phosphorylated by Syk, provides docking sites for Btk and PLCg2, and thereby facilitates PLCg2 phosphorylation and activation by Btk (Hayashi et al., 2000; Xu et al., 2000; Baba et al., 2001) . Btk is itself activated by Src kinases, when it is recruited to the plasma membrane through an interaction with phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ), a major lipid product of the PI3-K. Once activated, phospholipase Cg2 (PLCg2) hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to produce inositol-3,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG), which in turn activate Ca 2+ mobilization and protein kinase C (PKC), respectively (Scharenberg and Kinet, 1998; Kurosaki et al., 2000) . It is believed that these latter second messengers are responsible for transcription factor activation and ultimately B-cell activation and proliferation, although the exact molecular mechanisms and signalling intermediates involved are not yet defined.
B-cell activation and proliferation involve entry into the cell cycle from a resting or quiescent state (G0 phase) and successful progression through G1 (gap-phase 1), S (DNA synthesis), G2 (gap-phase 2), and M (mitosis) of the cell cycle. Progression through each phase of the cell cycle is controlled by cooperative activity of specific cyclin-dependent kinases (CDKs) and their regulatory subunits, cyclins (Lauper et al., 1998; Sherr and Roberts, 1999; Sherr, 2000) . Essentially, the D-type cyclins (cyclin D1, D2 and D3) in association with CDK4 and CDK6 are responsible for G1 phase progression, while the CDK2-cyclin E (E1 and E2) complex is important for initiation of S phase. Progression through S phase is controlled by the CDK2-cyclin A complex, while the transition from G2 to M is mediated by CDC2-cyclin B. The principal cellular substrates of the cyclin-CDKs are members of the retinoblastoma protein (pRB) family of pocket proteins (pRB, p107 and p130) (Dyson, 1998; Grana et al., 1998) . In G0 and early G1, hypophosphorylated pocket proteins bind to transcription factors, such as E2F, thereby negatively regulating transcription of genes required for entry into and transition through S phase of the cell cycle (Lam and La Thangue, 1994; Sardet et al., 1997) . During cell-cycle progression, hyperphosphorylation of pRB is initiated by cyclin D-CDK4/6 in G1 and is completed by cyclin E-CDK2 and cyclin A-CDK2 in G1 and S phases (Sardet et al., 1997; Sherr and Roberts, 1999; Sherr, 2000) . Cyclin-CDKs are negatively regulated by two groups of CDK-inhibitors (CKIs), the CIP/KIP and the INK4 families of proteins (Sherr and Roberts, 1999; Sherr, 2000) . The CIP/KIP  proteins (p21   Cip1   , p27 Kip1 and p57
Kip2
) target both cyclin D-CDK4/6 and cyclin E/A-CDK2 by binding to the cyclin-CDK complexes, while the INK4 family members (p15  INK4b , p16  INK4a , p18  INK4c and p19 1NK4d ) inhibit cyclin D-CDK4/6 complex formation through direct association with the CDK components. The CIP/KIP proteins are potent inhibitors of cyclin E-and Adependent CDK2, but also act as assembly factors for cyclin D-dependent kinases at low stoichiometric levels. In B cells, we have identified cyclin D2 as the key regulator of cell-cycle progression and pocket protein phosphorylation in response to BCR stimulation (Lam et al., 1999 Banerji et al., 2001) .
The Btk-deficient xid mice display B-cell related developmental defects, including reduced IgM and IgG3 levels, impaired T-independent antibody responses and depletion of CD5 + (B1) lymphocytes (Khan et al., 1995; Rawlings et al., 1996) . B cells from these mice also fail to proliferate in response to anti-IgM stimulation (Brorson et al., 1997) . These 'Xid' phenotypes are also shared by mice deleted of components of the B-cell signalosome (p85a, Btk, BLNK and PLCg2) and downstream signalling intermediates, such as protein kinase C beta (PKCb) (Kurosaki, 1999 (Kurosaki, , 2000 . The molecular basis for the 'Xid' phenotype has not been defined. Interestingly, our previous studies show that mice deleted of cyclin D2 also exhibit 'Xid'-like phenotypes, thus suggesting that cyclin D2 is on the same signalling axis as the B-cell signalosome (Solvason et al., 2000) . Although the B-cell signalosome has been shown to be involved in BCR-induced cell activation and proliferation, the molecular mechanisms and signalling events linking the B-cell signalosome to cellcycle progression are not yet known. In this study, we used B cells derived from mice deficient for p85a, Btk and selective pharmacological inhibitors to investigate the effects of inactivation of the B-cell signalosome on cell-cycle phase progression and expression of cell-cycle regulators in response to BCR stimulation. Our results show that cyclin D2 is a downstream target of the B-cell signalosome on the BCR signalling axis and plays an essential role in integrating the BCR signals with the cell-cycle machinery to promote cell-cycle progression. Given that cyclin D2 deletion leads to 'Xid'-like immunodeficiency, our data also suggest the possibility that the B-cell proliferative and developmental defects observed in the mice deficient of B-cell signalosome components could be linked to their failure to induce cyclin D2 expression.
Experimental procedures

B-cell isolation and cell culture
Male (Xid) and female (normal) (CBA/N Â C57BL10)F1 mice colonies (Klaus et al., 1997) were maintained at the National Institute for Medical Research, UK and used at 6-12 weeks of age. The p85a-deficient mice have previously been described (Suzuki et al., 1999) and were housed at the Imperial College Animal Facilities. Singlecell suspensions were prepared from spleens of p85a null or xid mice and their normal counterparts by previously published methods (Johnson-Leger et al., 1998) . Briefly, T cells were killed by a cocktail of monoclonal antibodies against Thy-1, CD4 and CD8, plus guinea pig complement. Small, dense B cells were then isolated on Percoll density gradients, and erythrocytes were depleted by treatment with lysis solution consisting of 0.15 m NH 4 Cl. These preparations typically consisted of 90-95% B lymphocytes, and the yield of p85a null or xid B cells was usually about a third compared with the normal B cells. The cells were cultured at 10 6 cells per ml in RPMI 1640 medium supplemented with 5% foetal calf serum, 2 mm glutamine, 100 U/ml penicillin/streptomycin and 50 mm 2-mercaptoethanol, and were stimulated with 10 mg/ml of polyclonal antiIgM (affinity-purified F(ab') 2 goat anti-mouse purchased from Cappel/ICN) or lipopolysaccharide (LPS: E. coli, serotype O55:B5) (Sigma). The calcium flux inhibitor SK&F 96365 (Merritt et al., 1990) , ionomycin and phorbol 12-myristate 13-acetate (PMA) (Klaus et al., 1986) were obtained from Sigma, UK and used at 10 mg/ml, 1 mg/ml and 20 mg/ml, respectively. LFM-A13 (Mahajan et al., 1999) , LY294002 (Vlahos et al., 1994) , Wortmannin (Arcaro and Wymann, 1993) , U73122 (Hahner et al., 1991; Thompson et al., 1991) and Go¨6850 (Fasolato et al., 1990) were acquired from Calbiochem (La Jolla, CA, USA), and were administered at concentrations of 100 mm, 30 mm, 50 mm, 10 mm and 50 mm, respectively.
Cell-cycle analysis
Cell-cycle analyses were performed by combined propidium iodide (PI) and FITC staining as described (Williams et al., 1997) . Briefly, cells were washed with PBS and fixed in 90% ethanol/10% PBS. Following fixation, cells were washed again and then incubated with 50 mg/ml DNase-free RNase, 50 mg/ml PI and 0.1 mg/ml FITC for 30 min at 371C prior to analysis using a FACScan flow cytometer (Becton Dickenson).
Western blot analysis and antibodies
Western blot whole-cell extracts were prepared by lysing cells with four times packed cell volume of lysis buffer (1% Nonidet P-40, 100 mm NaCl, 20 mm Tris pH 7.4, 10 mm NaF, 1 mm sodium orthovanadate and protease inhibitors ('Complete' purchased from Boehringer Mannheim) on ice for 15 min. Protein yield was quantified by Bio-Rad Dc protein assay kit (Bio-Rad). Owing to the large number of apoptotic cells resulting from some of the treatments, samples were loaded with equal protein rather than by cell number. A measure of 50 mg of lysate was separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and recognized by specific antibodies. The antibodies against cyclin D2 (M-20), cyclin D3 (18B6-10), cyclin E (M-20), CDK2 (M2), CDK4 (C-22), CDK6 (C-21), p27 (C-19) p107 (C-18) and pRB (C-15) were purchased from Santa Cruz Biotechnology. The antiphospho pRB (Ser807/811) antibody was purchased from New England Biolabs and the anti-phospho pRB (Thr821) antibody from Biosource. The anti-p130 (anti-pRB2) (K25020) monoclonal antibodies were acquired from Transduction Laboratories. The antibodies were detected using horseradish peroxidase-linked goat anti-mouse or anti-rabbit IgG (Dako), or mouseabsorbed goat anti-rat IgG (Southern Biotechnology Associates, Inc.) and visualized by the enhanced chemiluminescent (ECL) detection system (Amersham Pharmacia Biotech, UK).
Results
Cell-cycle analysis of B cells from p85a null, xid and wild-type mice
The PI3-K regulatory subunit p85a and the tyrosine kinase Btk are two critical components of the B-cell signalosome. Previous thymidine incorporation studies have shown that antigen receptor-mediated proliferative responses of B cells from mice deficient for p85a or Btk are severely compromised (Fruman et al., 1999; Suzuki et al., 1999) . This inability of p85a À/À or btk À/À B cells to proliferate upon BCR engagement could be a result of a failure in cell-cycle entry into G1 or progression into S phase of the cell cycle. To identify the proliferative defects in these B cells deficient for p85a and Btk, we examined the kinetics of cell-cycle entry and progression of small, dense resting B cells following stimulation with either anti-IgM or LPS (lipopolysaccharide). Cell-cycle entry/progression was determined by flow cytometric analysis of both DNA and protein content, using PI and FITC staining, respectively. The unstimulated normal, p85a null ( Figure 1a ) and xid B cells ( Figure 1b ) were all found to have a 2N DNA content and a low protein content, indicating that the majority of these cells were in G0 phase of the cell cycle before mitogenic stimulation. Following LPS stimulation, a significant number of wild-type B cells started to enter G1 at 24 h, as revealed by an increase in their protein content. By 48 and 72 h following LPS treatment, a substantial number of the wild-type B cells had a high protein content and an increased DNA content, suggesting that they had entered S and G2/M phases. Both the p85a null and xid B cells proliferated in response to LPS stimulation, but progressed through the cell cycle with slower kinetics, with the majority of the cells entering G1 and S only at 48 and 72 h, respectively. Consistent with our previous results, the wild-type B cells stimulated with anti-IgM advanced through the cell cycle with slower kinetics when compared with the LPS-stimulated cells. The majority of the anti-IgM stimulated normal cells entered G1 and S phases at 48 and 72 h, respectively. After anti-IgM treatment, a fraction of the p85a null and xid B cells began to enter G1 phase by 24 h (as revealed by their increase in protein content), but did
The B cell signalosome targets cyclin D2 in BCR signalling J Glassford et al Figure 1 (a) Cell-cycle analysis of B cells from p85a null and wild-type mice. Small dense B cells from p85a null and normal mice were cultured with either anti-IgM (10 mg/ml) or LPS (10 mg/ml) for the indicated times. Cells were permeablized and stained with PI and FITC to measure DNA (X-axis) and protein (Y-axis) content, respectively, prior to FACS analysis. The percentages of cells in each phase of the cell cycle (G0, G1, S and G2/M), determined by their protein and DNA contents, are indicated. (b) Cell-cycle analysis of B cells from xid and wild-type mice. Small dense B cells from xid and wild-type mice were treated as described in (a)
The B cell signalosome targets cyclin D2 in BCR signalling J Glassford et al not advance further into S phase. The result also showed that a large number of the anti-IgM stimulated p85a null and xid B cells displayed a sub-2N DNA content compared with wild type, indicative of apoptosis. PI3-K has a well established role in mediating cell survival (Cantley, 2002) , and the increased apoptosis observed in these knockout mice might be due to disruption of this or other survival pathways. These data suggested that p85a null and xid B cells are able to enter the cell cycle in response to anti-IgM stimulation, but fail to induce DNA synthesis.
p85a null and xid B cells fail to induce cyclin D expression in response to BCR stimulation
To investigate the underlying mechanism responsible for the proliferative defects in p85a null and xid B cells, we examined the expression of cell-cycle regulators in B cells following anti-IgM and LPS treatment. Western blot analysis showed that cyclin D2 was undetectable in small dense (G0) B cells, but was induced by 24 h in the wild-type B cells stimulated with anti-IgM and in both the normal and mutant (xid and p85a null) B cells following LPS treatment (Figure 2a and b) . In contrast, no induction of cyclin D2 expression was detectable in either the xid or p85a null B cells stimulated with anti-IgM over the 72 h time course. The catalytic partners of cyclin D2, CDK4 and 6 were at basal levels in unstimulated B cells and their levels increased dramatically at 24 h after BCR stimulation, coinciding with cyclin D2 induction. The induction of cyclin D2, CDK4 and 6 expression coincided with cell-cycle entry and was followed by induction of cyclin D3, cyclin E, cyclin A and CDK2 expression at 48 h. We next used phospho-pRB antibodies specifically recognizing CDK4/6 and CDK2 phosphorylated residues to monitor the in vivo cyclin D-CDK4/6 and cyclin E-CDK2 activity in these B cells after anti-IgM and LPS treatment. The CDK4/6 phospho-pRB(Ser 807/811
) antibody revealed that the cyclin D-CDK4/6 activity was induced by 24 h in the anti-IgM stimulated wild-type B cells and the LPS treated wild-type and mutant B cells. This induction of cyclin D-CDK4/6 activity was concomitant with cyclin D2 and CDK4 and 6 induction, but preceded the upregulation of cyclin D3 expression at 48 h, indicating cyclin D2 but not cyclin D3 is responsible for the induction of CDK4/6 activity and subsequent cell-cycle entry in these cells. As predicted, the CDK2 specific pRB(Ser 807/811 ) antibody showed that the induction of cyclin E-CDK2 activity coincided with the upregulation of cyclin E and CDK2 expression at 48 h. Notably, the cdk inhibitor p27
Kip1 was downregulated in both the mutant and normal B cells following anti-IgM and LPS treatment. This downregulation of the cdk inhibitor, p27 was concomitant with the induction of cyclin D2. D-type cyclins are The B cell signalosome targets cyclin D2 in BCR signalling J Glassford et al thought to be responsible for sequestering p27 Kip1 and their activation ultimately leads to its degradation in response to mitogenic stimuli . However, the decrease in p27
Kip1 levels in the mutant B cells after anti-IgM treatment could also be the result of nonspecific protein degradation as a result of cells undergoing apoptosis.
Costimulation of resting B cells with PMA and ionomycin induces cyclin D2 expression and cell-cycle progression PKC and intracellular Ca 2+ flux have been demonstrated to be the major effectors of the B-cell signalosome. Upon BCR engagement, PL Cg2 catalyses the conversion of PIP 2 to IP 3 and DAG, which in turn activate intracellular calcium mobilization and PKC, respectively. In the previous section, our result suggested that BCR signals target cyclin D2 via the B-cell signalosome to mediate cell-cycle progression. We next investigated the signalling events immediately downstream of the B-cell signalosome, which are responsible for cyclin D2 induction. To this end, we treated small resting B cells with Ca 2+ ionophores and/or phorbol myristate acetate (PMA), which have been shown to activate intracellular Ca 2+ mobilization and PKC, respectively. Cell-cycle analysis (Figure 3a) showed that addition of the Ca 2+ ionophore ionomycin was insufficient to stimulate the cells to enter the cell-cycle, with most cells displaying a sub-2n DNA content by 72 h, indicative of apoptosis. Similarly, while PMA induced a small proportion of the resting B cells to enter the cell cycle, as indicated by an increase in their protein content, there was no subsequent increase in DNA content. In contrast, when small dense B cells were treated with ionomycin plus PMA, a significant proportion entered G1 and S by 24 and 48 h, respectively. In agreement with this, Western blot analysis (Figure 3b) showed that neither PMA nor ionomycin alone could effectively upregulate cyclin D2 expression, but PMA and ionomycin together induce cyclin D2 expression and subsequently the expression of other CDK complexes and their associated activity. This indicates that cellcycle progression into S phase requires the coactivation of both the PKC-and Ca
2+
-dependent signalling pathways. Treatment of cells with these drugs, in particular with ionomycin alone, was associated with a significant amount of apoptosis, indicating that other pathways also need to be activated by the BCR to mediate cell survival. Consistent with the cell-cycle analysis result, costimulation with ionomycin and PMA culminated in cyclin D2 expression followed by activation of its dependent kinases (CDK4/6). These results imply a cooperative role for both calcium signalling and PKC in cyclin D2 induction. These data also show that both Ca 2+ flux and PKC contribute to the induction of cyclin D2 expression and the accumulation of active and functional cyclin D-CDK4/6 complexes but possibly, via different mechanisms. Given that the second messengers intracellular calcium and PKC are the downstream effectors of the signalosome, this finding provides further biochemical evidence that the B-cell signalosome targets cyclin D2 to mediate cell-cycle progression.
Pharmacological inhibition of Ca
2+ signalling, PKC, Btk, PI3-K and PLCc activity blocks cell-cycle proliferation and cyclin D2 induction following BCR engagement To obtain further evidence that calcium signalling is required for the BCR-induced cyclin D2 expression and cell-cycle progression, we examined the effects of SK&F 96365 (Merritt et al., 1990) , a specific antagonist of receptor-operated capacitative Ca 2+ entry, on small dense resting B cells following BCR stimulation. Consistent with our previous result, SK&F 96365 was able to block the induction of cyclin D2 expression mediated by BCR engagement (Figure 4) . We further demonstrated that SK&F 96365 was able to block the S phase entry (Table 1) , and the accumulation of functional CDK4/6 and CDK2-dependent kinase activity and the subsequent expression of cell-cycle regulators, including cyclin D3, E and A and CDK2, 4 and 6 (Figure 4 ). Also consistent with our previous results, inhibition of PKC with Go¨6850 (also called GF109203X and bisindolylmaleimide I) (Toullec et al., 1991) was able to block cyclin D2 induction (Figure 4 ) and cellcycle progression (Table 1 ), indicating that PKC is also required for BCR-induced cyclin D2 expression and subsequent cell-cycle progression.
To further confirm our results from the Btk and p85a null B cells, we also pretreated small resting B cells with LFM-A13 and LY294002, specific inhibitors of Btk and PI3-K, respectively, prior to anti-IgM stimulation. The result showed that both LMF-A13 and LY294002 (or Wortmannin) could effectively inhibit cyclin D2 expression ( Figure 4 ) and cell-cycle transition through G1 in response to anti-IgM, thus providing further evidence that both Btk and the PI3-K are essential for cyclin D2 expression and cell-cycle progression. Similar results were obtained with Wortmannin, another specific PI3-K inhibitor which functions differently from LY294002. This finding was further strengthened by the observation that the induction of cyclin D2 and S phase cell-cycle entry in response to anti-IgM was also blocked by the presence of U73122, a specific PLCg inhibitor (Thompson et al., 1991) . It is also interesting to note that inhibition of the PI3-K and most of the signalling pathways downstream of the B-cell signalosome that were studied resulted in increased cell death when cells were stimulated via their BCR (Table 1) . These data reinforce those obtained with the mice null for B-cell signalosome components which also showed increased cell death upon BCR stimulation.
Discussion
While B-cell signalosome regulation and activation events have been studied extensively, the downstream BCR signalling events required for B-cell activation and proliferation remained relatively undefined. In the present study, we examined the molecular basis responsible for the proliferative defects observed in B cells
The B cell signalosome targets cyclin D2 in BCR signalling J Glassford et al deficient for Btk and the p85a subunit of PI3-K, two signalling molecules central to the function of the B-cell signalosome. We showed that Btk and p85a deficient B cells failed to upregulate cyclin D2 expression in response to BCR engagement. This result is further confirmed by studies showing that specific pharmacological inhibitors of Btk (LFM-A13) and PI3-K (LY294002 and Wortmannin) also block cyclin D2 expression in response to BCR engagement. These data provide evidence for the concept that the B-cell signalosome is involved in regulating cyclin D2 expression in response to BCR engagement. Further strengthening of this notion, lies in the fact that the specific PLCg inhibitor U73122 also blocks cyclin D2 expression Figure 3 (a) Effects of PMA and ionomycin on cell-cycle progression. Small dense wild-type B cells were treated with either PMA, ionomycin or both. Cells were collected at 0, 24 and 48 h after different treatments and prepared for cell-cycle analysis as described for Figure 1a . Effect of PMA and ionomycin on the expression of cell-cycle regulatory proteins. Lysates were prepared from small dense B cells treated as described for Figure 4a and used for Western blot analysis for cell-cycle regulatory proteins, including cyclin-D2, -D3, -E, and -A, CDK2, -4, and -6, p27
Kip1 , pRB, p107 and p130
The B cell signalosome targets cyclin D2 in BCR signalling J Glassford et al in response to anti-IgM stimulation. This idea is further supported by a recent study showing that BLNK, another key component of the B-cell signalosome, is also required for cyclin D2 expression and subsequent cell-cycle progression in response to BCR engagement (Tan et al., 2001) . Our data show that LPS stimulates cyclin D2 expression and subsequent cell-cycle progression through a mechanism independent of the activity of p85a and Btk. This also indicates that the p85a-and Btk-deficient B cells do not have a general proliferative defect and the inability to induce cyclin D2 expression and cell-cycle progression is specific to BCR signalling. It is interesting to note that on all occasions when B-cell signalosome components are inactivated by pharmacological inhibitors or by targeted gene disruption, the small resting (G0) B cells failed to progress into late G1 and S phases. This defect in G1 to S transition is consistent with their failure to induce cyclin D2 expression, as cyclin D activity is required for the transition through G1 phase (Sherr, 2000) . We also observed that, besides defective proliferative responses, p85a À/À and Btk À/À B cells also have a higher apoptotic rate in culture in vitro and in response to BCR stimulation when compared with wild-type B cells. B cells derived from mice deleted of the B signalosome components, including the PI3-K catalytic subunit p110d, BLNK and PLCg2, have also been reported to be prone to spontaneous as well as BCR-induced Small dense wild-type B cells were stimulated with 10 mg/ml of anti-IgM in the absence or presence of 10 mg/ml SK&F 96365, 100 mm LFM-A13, 30 mm LY294002, 50 nm Wortmannin, 10 mm U73122, or 50 nm Go¨6850. Cells were collected at 0, 24 and 48 h after anti-IgM and used for cell-cycle analysis and Western blot analysis for cell-cycle regulatory proteins. The percentages of cells in each phase of the cell cycle are shown in Table 1   Table 1 Effects of specific B-cell signalosome inhibitors on the fraction of cells in different cell cycle phases following anti-IgM treatment. The percentages of cells in G0, G1, S and G2/M following anti-IgM treatment in the presence and absence of specific B-cell signalosome inhibitors. Cells were treated as described for Figure 4 and analysed as described for Figure 1a o2n The B cell signalosome targets cyclin D2 in BCR signalling J Glassford et al apoptosis (Wang et al., 2000; Tan et al., 2001; Okkenhaug et al., 2002; Clayton et al., 2002) . Previous gene targeting experiments have demonstrated that signals transduced via BCR promote survival of quiescent mature B cells (Lam et al., 1997) . Other studies have demonstrated that Btk is required for the induction of the antiapoptosis Bcl-2 family member, Bcl-xL, via the transcription factor NF-kB in B cells (Petro et al., 2002) . It is therefore likely that p85a and Btk participate in the formation of the multi-component B-cell signalosome complexes which are required for the expression of the survival protein Bcl-xL following BCR stimulation, and pertubation of this B-cell signalling axis contributes to defective Bcl-xL expression and thus compromised survival of B cells. Consistent with this idea, B cells defective for other components of the B signalosome, such as p110d and BLNK, have been shown to express a lower basal level of Bcl-xL compared with their wild-type counterparts (Tan et al., 2001; Clayton et al., 2002) . These p110d and BLNK deficient B cells also fail to induce the activation of NF-kB and expression of Bcl-xL in response to BCR crosslinking (Tan et al., 2001; Clayton et al., 2002) . Moreover, recent studies using PKCb null B cells have demonstrated that PKCb is essential for NF-kB activation and Bcl-xL expression in response to BCR stimulation through regulation of IkB and IkB kinase a (Saijo et al., 2002) . Similarly, we have also obtained preliminary data showing that p85a À/À and Btk À/À B cells fail to induce Bcl-xL protein expression in response to BCR crosslinking (unpublished data). More recent evidence from PKCb deficient B cells demonstrates that PKCb is essential for NF-kB activation and Bcl-xL expression upon BCR stimulation through regulation of IkB and IkB kinase a (Saijo et al., 2002) . Together, these studies suggest that BCR-stimulation activates survival events such as activation of PKCb and NF-kB and expression of Bcl-xL via the B-cell signalosome, and that deletion of B signalosome components renders these B cells susceptible to BCR-induced apoptosis. The higher levels of spontaneous apoptosis observed for these B signalosome component defective B cells probably reflect the fact that this signalling axis also participates in signal transduction in response to extracellular stimuli which are transmitted via other cellular receptors, including those for the growth factors, cytokines, G-proteins, etc. (Qiu and Kung, 2000) . Another possible mechanism whereby B cells null for B signalosome components undergo increased apoptosis may be by pertubation of the PI3-K/PKB signalling pathway. Supporting this notion, B cells lacking the PI3-K subunit p110d, which fail to activate PKB, are susceptible to apoptosis (Clayton et al., 2002) . Protein kinase B (PKB, also called Akt) is activated by PI3-K via its PH domain which interacts with PI(3,4,5)P 3 . Once activated, PKB in turn, phosphorylates and inactivates the Forkhead (also termed FoxO) family of transcription factors that are responsible for activating the proapoptotic Bcl-2 family member, Bim (Dijkers et al., 2002) . Similarly, PKB also phosphorylates and inactivates the Bcl-2 family member, Bad, preventing it from inhibiting the survival response mediated by Bcl-2 and Bcl-xL (Scheid and Duronio, 1998; Downward, 1999 Protein kinase C (PKC) is a group of enzymes that are physiologically activated by 1,2-diacylglycerol (DAG). Phorbol esters (e.g. PMA) are analogues of the second messenger 1,2-diacylglycerol (DAG) and can mimic DAG function in activating PKC (Nishizuka, 1992) . Using ionomycin and PMA, we provide evidence indicating that synergistic signalling by PKC and intracellular calcium is essential for the BCR-induced cyclin D2 expression and subsequent cell-cycle progression. We showed that activation of either PKC or the calcium-dependent signalling pathway alone can induce resting B cells to enter G1 but not S phase of the cell cycle. Of particular importance is that effective cell cycle entry and progression requires costimulation with both PMA and ionomycin. The cooperativity between PKC and calcium-dependent signalling in promoting B cellcycle progression is highlighted by the fact that neither PMA nor ionomycin alone can effectively induce cyclin D2 expression and formation of active functional CDK4/6 and CDK2 complexes. This observation further confirms our hypothesis that the B-cell signalosome targets cyclin D2 to mediate cell-cycle progression. The combined effects of Ca 2+ ionophore and PMA mimic the effects of BCR engagement, by providing the two second messengers (Ca 2+ flux and PKC) normally generated through breakdown of PIP 2 by PLCg2.
Our data also demonstrate that while treatment with ionomycin and PMA together induce cell-cycle progression, treatment of B cells with the calcium ionophore ionomycin alone accelerates apoptosis. This observation is in agreement with previous studies showing that the phorbol ester PMA can block the ionomycin-induced growth arrest and apoptosis (Muthukkumar et al., 1993) . The mechanism by which PMA protects cells from Ca 2+ -triggered apoptosis is not fully understood, but has been shown to be at least partially mediated through activating PKCs (King et al., 1999) . Alternatively, phorbol ester has also been shown to indirectly block the increase in PIP 2 hydrolysis and calcium flux in response to BCR stimulation or ionomycin treatment (King et al., 1999) . BCR-induced proliferation of mature B cells is associated with an increase in intracellular Ca 2+ levels and PIP 2 hydrolysis, and it has been suggested that immature B cells undergo BCR-induced apoptosis because of their inability to hydrolyse PIP 2 and activate PKCs to counteract the proapoptotic increase in Ca 2+ flux triggered by BCR stimulation (King et al., 1999) . This BCR-induced apoptosis can be recapitulated in mature B cells when PKC activation is uncoupled by the presence of PKC inhibitor (e.g. Go¨6850; our data) or PKC deletion (Leitges et al., 1996) . In support of this hypothesis, we have previously shown that overexpression of Bcl-xL protein, an established downstream target of PKC, can block immature B cells from undergoing apoptosis triggered by BCR crosslinking (Lam et al., 1998) . These findings together indicate that BCR stimulation not only activates survival but also apoptotic signalling events, and an imbalance of these BCR-induced signals can have a dramatic effect on the viability of B cells.
We also showed that the BCR-mediated cyclin D2 induction could be abolished by pretreatment of resting B cells with specific inhibitors of capacitative Ca 2+ entry or PKC. Using SK&F 96365 which selectively blocks the capacitative Ca 2+ entry (CCE) (Fasolato et al., 1990) , we confirmed further that Ca 2+ signalling is required for cyclin D2 expression and cell-cycle progression in B cells in response to BCR stimulation. In addition, we demonstrated that the specific PKC inhibitor Go¨6850 can efficiently block cyclin D2 expression and cell-cycle progression into S phase.
Mice deleted of components of the B-cell signalosome display 'Xid' phenotypes, including loss of B1 cells, reduced serum IgM and IgG3 levels, impaired Tindependent antibody response and absence of B cell proliferative response to anti-IgM (Fruman et al., 2000; DeFranco, 2001) , which are also shared by cyclin D2-deficient mice (Solvason et al., 1998; Lam et al., 2000) . The present finding that cyclin D2 functions downstream of the B-cell signalosome on the BCR signalling axis provides biochemical evidence to explain the genetic link between cyclin D2 and signalling intermediates of the B cell signalosome. Collectively, these findings suggest the possibility that the Xid-like phenotype observed in B cells deleted of signalosome molecules (Fruman et al., 2000; DeFranco, 2001 ) may be linked to their inability to induce cyclin D2 expression. Interestingly, the B-cell defects observed in mice deficient for signalosome components, including p85a, Btk, BLNK and PLCg2, are more severe compared with cyclin D2 null mice (Solvason et al., 2000) . Mice null for p85a, Btk, BLNK and PLCg2 have few mature B cells, while cyclin D2-deficient mice have nearly normal numbers of IgM + B cells. This probably reflects the fact that the signalosome components function further upstream of the BCR signalling cascade and have additional roles in B-cell development compared with cyclin D2. Indeed, deletion of BCR components and Syk results in an even more severe B-cell developmental defects than xid, including a nearly complete block in development at the pro-B to pre-B cell stage (Kurosaki, 2000; Cariappa and Pillai, 2002) . Interestingly, PKCb deficient mice have a nearly identical phenotype to cyclin D2 null mice and have almost normal numbers of mature B cells, suggesting a close functional and signalling link between PKCb and cyclin D2 (Leitges et al., 1996; Solvason et al., 2000) .
Alternative mechanisms that relay the BCR signals to cyclin D2, but may not involve the B-cell signalosome, have also been documented. We have recently shown that the Rho family GTP exchange factor Vav is also involved in the induction of cyclin D2 expression and subsequent proliferation of B cells in response to BCR stimulation Figure 5 A model of the B-cell signalosome linking BCR engagement with cyclin D2 expression. BCR stimulation leads to activation of nonreceptor PTKs, including Syk and the Src family of kinases Lyn, Fyn and Blk, culminating in the assembly and activation of the B-cell signalosome p85a, Btk, BLNK and PLCg2. This triggers the conversion of PIP2 into IP 3 and DAG, which promote [Ca 2+ ] i flux and PKC activation, respectively. The latter two signalling events cooperate to induce cyclin D2 expression and thus cell-cycle progression. BCR engagement also induces Vav to activate PIP 5-kinase, which in turn converts PIP to PIP2, the substrate used by PLCg2 to generate DAG and IP 3
The B cell signalosome targets cyclin D2 in BCR signalling J Glassford et al which are similar to those identified in cyclin D2 À/À , xid and p85d À/À mice. Although there is no evidence to suggest that Vav functions inside the B-cell signalosome, it has previously been proposed that signalling pathways downstream of Vav and the B-cell signalosome converge on PIP2 (DeFranco, 2001) . Previous studies show that PI 4-phosphate (PIP) 5-kinase, a downstream target of Vav in the BCR signalling pathway, is responsible for converting PIP to PIP2, the substrate used by the phospholipase PLCg to generate the [Ca 2+ ] i (intracellular calcium)-mediator IP 3 and the PKC activator DAG (O'Rourke et al., 1998; Satterthwaite et al., 1998) . However, an interaction between Vav and BLNK has been documented (Fu and Chan, 1997; Fu et al., 1998) , and since Vav also contains several protein-protein interaction domains, Vav may have a role in the signalosome structure.
It is not yet clear how the B-cell signalosome integrates its signal with cyclin D2. It should be informative to define the signalling events downstream of PKC and Ca 2+ flux, which are responsible for cyclin D2 induction. A recent report showed that the transcription factor STAT5A is a downstream target of Btk in B cells (Mahajan et al., 2001) . Interestingly, STAT5 has also been demonstrated to be able to activate the expression of the cyclin D2 promoter (Martino et al., 2001) . It is therefore possible that STAT5 might have a role in activating cyclin D2 transcription in response to BCR signalling via the B-cell signalosome. However, it is likely that multiple signalling events cooperate to induce cyclin D2 expression as we have shown recently that cyclin D2 expression can be regulated by both transcriptional and post-translational mechanisms in response to BCR signalling in immature B cells .
In summary, our present results lead us to propose a model in which the B-cell signalosome (p85b, Btk, BLNK and PLCg2) targets cyclin D2 via the Ca 2+ and PKC-dependent signalling cascades to mediate cell-cycle progression in response to BCR engagement ( Figure 5 ). These findings also place cyclin D2 downstream of the B-cell signalosome on the BCR signalling axis. Our previous work demonstrates that cyclin D2 deficient mice display a 'Xid'-like phenotype and that induction of cyclin D2 expression is a crucial molecular event which links BCR stimulation to cell-cycle progression. Taken together, these data also suggest that the molecular mechanism underlying the B cell proliferative and developmental defects observed in mice deleted of BCR signalling intermediates could be at least partially related to their failure to induce cyclin D2 expression. Moreover, signalling via the B-cell signalosome is required for both proliferative and survival functions, and deletion in components of this signalling axis can compromise the growth as well as survival of B cells.
